Ehsan Rahimy, MD

Articles by Ehsan Rahimy, MD

Patient and Cross-Care Education Strategies for AMD and DME

ByEhsan Rahimy, MD,Jonathan Jonisch, MD,Veeral Sheth, MD, MBA, FASRS, FACS,Ali Khan, MD, FACS, FASRS

June 22nd 2023

Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Barriers to Optimal Treatment Outcomes

ByEhsan Rahimy, MD,Jonathan Jonisch, MD,Veeral Sheth, MD, MBA, FASRS, FACS,Ali Khan, MD, FACS, FASRS

June 15th 2023

Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Overview of Anti-VEGF Treatments for AMD and DME

ByEhsan Rahimy, MD,Jonathan Jonisch, MD,Veeral Sheth, MD, MBA, FASRS, FACS,Ali Khan, MD, FACS, FASRS

June 15th 2023

Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

The Future of Treatment for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

February 3rd 2022

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

Emerging Treatment Options for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 27th 2022

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Diabetic Macular Edema: Faricimab

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 27th 2022

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Anti-VEGF Agents and Diabetic Retinopathy Severity Score

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 20th 2022

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Maintenance Treatment for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 20th 2022

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Considerations for Switching Diabetic Macular Edema Treatments

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Reviewing Anti-VEGF Agents in Clinical Practice

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Diabetic Macular Edema: Limitations of Anti-VEGF Agents

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Anti-VEGF Agents for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Treatment Options for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 30th 2021

Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.

Diabetic Macular Edema with Concomitant Conditions

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 30th 2021

A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.

Progression of Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 23rd 2021

A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.

Diagnostic Testing for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 23rd 2021

Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.

Pathophysiology of Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 16th 2021

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

An Overview of Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

December 16th 2021

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.

Initiating Conversations with Patients about Anti-VEGF Agents

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

December 13th 2021

Key opinion leaders emphasize important considerations when discussing the safety of anti-VEGF agents with patients and highlight unmet needs in nonproliferative diabetic retinopathy treatments.

Updates in the Management of Non-Proliferative Diabetic Retinopathy

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

December 8th 2021

Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.

A Review of Clinical Trial Data in Non-Proliferative Diabetic Retinopathy

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

December 8th 2021

A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.

Non-Proliferative Diabetic Retinopathy: Goals of Therapy

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

November 30th 2021

Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.

Early Detection of Non-Proliferative Diabetic Retinopathy

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

November 30th 2021

Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.

An Overview of Diabetic Retinopathy

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

November 22nd 2021

Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.

Making Informed Therapy Decisions for Macular Edema

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

November 22nd 2021

Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.

Efficacy and Safety of Anti-VEGF Agents for Macular Edema

ByW. Lloyd Clark, MD,Joseph M. Coney, MD,Diana V. Do, MD,Ehsan Rahimy, MD

November 15th 2021

Key opinion leaders review the efficacy and safety of available VEGF inhibitors for the treatment of macular edema and explain how effectiveness is evaluated.